News about the Enterprise's Stakeholders.

Grant Opportunity for Early Stage Investigators - November 11, 2010

The National Institute of Allergy and Infectious Diseases is funding a third round of the novel research initiative entitled “The Early Stage Investigator Scholar Award: Pilot Studies to Advance Non-Human Primate Models in Support of HIV Vaccine Clinical Research.”   For more details see   Interested applicants can submit a Letter of Intent to by 30 November 2010.  Full applications are due 5 January 2011.

New Lines of Attack in H.I.V. Prevention - November 9, 2010

The hottest news in AIDS in the last year was the partial success in a South African clinical trial of a microbicide.  Read the full New York Times article by Donald McNeil regarding the promise of microbicides upcoming PrEP results here.

New Study Shows Small Protein Changes Make Big Difference in Natural HIV Control - November 5, 2010

A new study published online in Science found that slight differences in the structure of a protein in the body that recognizes HIV could explain why some individuals infected with HIV are able to resist the onset of AIDS without treatment.  According to Dr.

AVAC Publications and Web site Survey - November 4, 2010

AVAC: Global Advocacy for HIV Prevention is seeking feedback to better understand how their materials and website are used and how they can be improved. AVAC asks advocates to complete the AVAC publications and web site survey here. The survey should take no more than 10-15 minutes to complete.

Sixth EDCTP Forum: opening of registration and call for abstracts - November 2, 2010

The theme of the forum is Strengthening Research Partnerships for Better Health and Sustainable Development, taking into account the past, present and future of EDCTP. For more information, click here.

HIV antibodies do control infection: new hope for vaccines and treatment - October 26, 2010

According to a single-patient study published in the October issue of Nature Communications, B-cells and neutralizing antibodies might control HIV levels better than scientists previously suspected. The authors of the study note that the finding could open a new avenue for both preventive and treatment vaccines for HIV. To view the full text of the study, please click here.

Building Bridges, Dismantling Walls - October 13, 2010

In an article in Global Health, Seth Berkley of IAVI discussed the role of recent scientific breakthroughs in the elicitation of sufficiently potent antibodies against many of the subtypes of HIV in circulation. According to Berkley, the recent renaissance in AIDS vaccine research and development is the reason the outlook for an AIDS vaccine is more promising today than ever. The full story can be read here.

Gates Foundation speaks to the value and impact of vaccines - October 7, 2010

AIDS Vaccine 2010 Effective Community Engagement in HIV Biomedical Research - October 6, 2010

The Global HIV Vaccine Enterprise co-sponsored a satellite on community engagement to identify strategies to enhance research partnerships among diverse stakeholders in HIV biomedical research. The meeting was recorded and can be accessed here (requires free WebEx software installation).

RV144: One Year Later - MHRP Releases Statement on 1 Year Anniversary of Results - September 24, 2010

The U.S. Military HIV Research Program (MHRP) issued a statement on the one-year anniversary of the announcement of the results of RV144, the trial in Thailand that showed the first evidence that a vaccine is able to reduce risk of HIV infection in humans. The statement is available here:

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account